ALKS — Alkermes plc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1520262 ·
Last close
$48.99
Market Cap
$8.22B
52W High
$55.67
52W Low
$33.12
ADV30
2,439,747
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 392,911,000 | 331,333,000 | -48,280,000 | -66,480,000 | 4,258,076,000 | 351,551,000 | 2,506,545,000 |
| Dec 2025 | 384,547,000 | 338,338,000 | 58,104,000 | 49,341,000 | 2,486,993,000 | 388,570,000 | 667,698,000 |
| Sep 2025 | 394,185,000 | 342,594,000 | 89,082,000 | 82,761,000 | 2,329,512,000 | 616,449,000 | 596,080,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$256,200,000
Investing CF
$-1,790,605,000
Financing CF
$1,486,151,000
CapEx
$-44,530,000
Dividends Paid
—
Buybacks
$-27,696,000
EPS Diluted TTM
$0.90
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-801,274,000
Inventory
$336,703,000
Receivables
$407,630,000
ST Investments
$160,311,000
EBIT TTM
$237,204,000
Pretax Income TTM
$204,035,000
Interest Exp TTM
$33,169,000
Analysts
17
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,667,651,968
EBITDA
$284,932,000
Free Cash Flow
$153,381,376
Enterprise Value
$9,309,184,000
Total Cash
$656,577,024
Total Debt
$1,572,563,968
Shares Out
167,763,272
Trailing EPS
$0.40
Book Value
$10.79
ROE
3.9%
ROA
4.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,475,899,000 | 253,956,000 | 241,664,000 | 2,486,993,000 | 667,698,000 | — | 520,754,000 |
| Dec 2024 | 1,557,632,000 | 420,636,000 | 367,070,000 | 2,055,567,000 | 590,590,000 | — | 439,124,000 |
| Dec 2023 | 1,663,405,000 | 414,122,000 | 355,757,000 | 2,136,223,000 | 933,537,000 | — | 401,353,000 |
| Dec 2022 | 1,111,795,000 | -6,089,000 | -158,267,000 | 1,963,978,000 | 920,225,000 | — | 21,044,000 |
TTM Snapshot
Revenues TTM
$399,082,000
NetIncome TTM
$-105,686,000
OpCashFlow TTM
$0
Assets (Latest)
$1,797,227,000
Forward EPS
$1.83
Max Pain — expiry 2026-08-21
max pain strike: $45.00 · spot: $48.99 · call oi: 10,339 · put oi: 4,206
Expected Move to 2026-08-21:
±$4.15
(8.47%) —
implied range
$44.84 –
$53.14
· ATM straddle on $49.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TGTX | TG THERAPEUTICS, INC. | $7.96B | $52.03 | — |
| SYRE | Spyre Therapeutics, Inc. | $8.54B | $98.33 | — |
| PRAX | Praxis Precision Medicines, Inc. | $8.58B | $307.83 | — |
| IONS | IONIS PHARMACEUTICALS INC | $8.60B | $51.77 | — |
| PTGX | Protagonist Therapeutics, Inc | $8.79B | $136.64 | — |
News headlines (Yahoo Finance, 1h cache)
Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says
2026-07-29 15:54 · Yahoo
Alkermes plc Q2 2026 Earnings Call Summary
2026-07-29 12:30 · Yahoo
Alkermes PLC (ALKS) Q2 2026 Earnings Call Highlights: Strong Sales Growth Amidst Competitive ...
2026-07-28 19:01 · Yahoo
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down
2026-07-28 15:21 · Yahoo
Alkermes Q2 Earnings Call Highlights
2026-07-28 14:04 · Yahoo
Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics
2026-07-28 13:30 · Yahoo
Alkermes (ALKS) Reports Break-Even Earnings for Q2
2026-07-28 12:15 · Yahoo
Alkermes plc Reports Second Quarter 2026 Financial Results
2026-07-28 11:00 · Yahoo
Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
2026-07-22 14:00 · Yahoo
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2026-07-21 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.